Recieved grant in 2025 

DCCC has funded 200.000 DKK to expand and continue the network. The network is part of the Danish national infrastructure for personalised medicine and serves as a national, interdisciplinary platform focused on ensuring consistent national standards for the analysis and interpretation of comprehensive genomic data in cancer treatment for Danish patients. 

The network aims to develop and strengthen collaboration with relevant stakeholders to ensure that its activities are coordinated with, and integrated into, other national initiatives. 

Planned activities in the coming period include: 

  • Annual workshops for bioinformaticians and variant interpreters 
  • Creating new working groups and continuing activities in current groups 
  • Strengthening partnerships with relevant stakeholders 
  • Assessing the potential of artificial intelligence in variant interpretation and linking annotated variants to treatment, with a dedicated working group established to draft a protocol and apply for funding 
  • Evaluating needs and opportunities for contributing to courses or training in the use of genomic data in cancer care for both professionals and patients 
  • Establishing a network website and increasing visibility of the network’s activities 

Participating members

  • Britt Elmedal Laursen, Consultant, Associate Professor, Department of Molecular Medicine (MOMA) & Department of Oncology, Aarhus University Hospital, Department of Biomedicine, Aarhus University 
  • Mads Sønderkær, Molecular Biologist, Department of Molecular Diagnostics, Aalborg University Hospital 
  • Martin Bøgsted, Head of Clinda, Clinical Data Science, Professor, Department of Clinical Medicine, Faculty of Medicine, Aalborg University Hospital 
  • Inge Søkilde Pedersen, Chief Laboratory Geneticist, Professor, PhD, Department of Molecular Diagnostics, Aalborg University Hospital 
  • Søren Vang, Lead Bioinformatician, Department of Molecular Medicine (MOMA), Aarhus University Hospital 
  • Mette Christiansen, Lead Molecular Biologist, Department of Molecular Medicine (MOMA), Aarhus University Hospital 
  • Henrik Hager, Consultant, Department of Pathology & Department of Molecular Medicine (MOMA), Aarhus University Hospital 
  • Maria Bibi Lyng, ead Molecular Biologist, Department of Pathology, Odense University Hospital 
  • Marianne Ingerslev Holt, Consultant, Department of Clinical Genetics, Hospital Lillebælt 
  • Malene Støchkel Frank, Chair of the Danish Society for Clinical Oncology, Consultant, Clinical Research Associate Professor, Department of Oncology and Palliative Care, Zealand University Hospital, Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen 
  • Estrid Høgdall, Clinical Professor, Department of Pathology, Herlev and Gentofte Hospital 
  • Frederik Otzen Bagger, Lead Bioinformatician, Department of Genomic Medicine, Rigshospitalet 
  • Christina Westmose Yde, Lead Molecular Biologist, Department of Genomic Medicine, Rigshospitalet 

 Leaders of experimental units in oncology departments and genomic screening programmes: 

  • Morten Ladekarl, Professor, Consultant, Department of Oncology, Aalborg University Hospital (PI Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment). 
  • Annette Kodahl, Head Consultant, Department of Oncology, Odense University Hospital (PI på PreCode, PREcision Medicine in Cancer in Odense, Denmark) 
  • Ulrik Lassen, Chief Medical Officer, Professor, Department of Oncology, Rigshospitalet (PI på CoPPo, Copenhagen Prospective, Personalized Oncology and ProTarget). 
  • Rikke Eefsen, Consultant, Department of Oncology, Herlev Hospital 
  • Kristoffer Rohrberg, Head Consultant, Department of Oncology, Rigshospitalet 

Danish National Molecular Tumor Board (DNMTB): Martin Højgaard, Specialty Registrar/ MD, PhD, Department of Oncology, Rigshospitalet 

Scientific Council at Danish National Genome Center (Chair of the Council): Ole Halfdan Larsen, Chief Medical Officer, Department of Molecular Medicine (MOMA), Aarhus University Hospital 

DMCG Committee for Genomic Tumour Profiling: Camilla Qvortrup, Chair of DMCG.dk 

The network is an extension of the Network for harmonising interpretation of somatic variants for treatment of patients with refractory cancer, established in 2017 with support from DCCC.